Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NTLA vs HRMY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HRMY Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 10–0 Matrix Metrics)

HRMY Overall Winner 6-Pillar Tally: NTLA 1 – 5 HRMY Matrix Metrics: NTLA 0 – 10 HRMY

As of Nov 16, 2026, Harmony Biosciences Holdings, Inc. (HRMY) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NTLA carries a Unified Composite Score of 49.9/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas HRMY carries 57.1/100 (HOLD) at $33.13 (5.6x Forward P/E, 22.2% operating margin).

  • Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile HRMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NTLA vs HRMY
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
TTM Revenue $53M
Forward P/E N/M
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.1%), weak momentum, RSI 39
RSI-14: 39.3 · SMA20: $11.58 · SMA50: $11.86
HRMY NASDAQ Head-to-Head Winner
Harmony Biosciences Holdings, Inc. Common Stock
Pharmaceutical Preparations
$33.13
-1.87% 1D
Market Cap $2.0B
TTM Revenue $989M
Forward P/E 5.6x
Beta / 30D Vol 0.60β · 45% Vol
Unified Composite Score
57.1 / 100 HOLD
Tech 56.0 Fund 63.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 35
RSI-14: 34.6 · SMA20: $35.86 · SMA50: $38.47

6-Pillar Scorecard Institutional Category Breakdown (NTLA 1 – 5 HRMY)

Columns: Metric · NTLA · HRMY
1. Valuation Multiples HRMY
Forward P/E N/M 5.6x
Trailing P/E N/M 11.2x
PEG Ratio N/M N/M
EV / Revenue 29.1x 1.5x
2. Growth & Scale HRMY
Revenue Growth (YoY) -48.0% +12.3%
Earnings Growth (YoY) +0.0% -6.9%
TTM Revenue (USD) $53M $989M
Market Cap $1.5B $2.0B
3. Profitability & Quality HRMY
Gross Margin N/A 74.0%
Operating Margin -826.0% 22.2%
Net Profit Margin 0.0% 18.1%
Return on Equity (ROE) -62.6% 18.7%
4. Balance Sheet & Cash Flow HRMY
Cash Generation (TTM) -$358M $323M
Cash Flow Margin N/A 32.6%
Net Cash / Leverage $74M Net Debt (0.38x D/E) $498M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning HRMY
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 101.3% (78th %ile) 41.5% (4th %ile)
Put/Call OI Skew 0.42x (Call-Skewed) 3.37x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat NTLA
OpEx & R&D Intensity N/A 51.8% of Rev ($512M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NTLA (0) vs HRMY (10)
Institutional Metric NTLA HRMY Criterion Row Edge
Market Capitalization
Scale
$1.5B $2.0B Larger Scale HRMY
Trailing P/E Ratio
Valuation
N/M 11.2x Lower Multiple HRMY
Forward P/E Ratio
Valuation
N/M 5.6x Lower Multiple HRMY
Revenue Growth (YoY)
Growth
-48.0% +12.3% Higher Growth HRMY
Operating Margin (TTM)
Profitability
-826.0% 22.2% Higher Margin HRMY
Net Profit Margin
Profitability
0.0% 18.1% Higher Margin HRMY
Return on Equity (ROE)
Capital Efficiency
-62.6% 18.7% Higher ROE HRMY
52-Week Range Position
Momentum
20% ($8–$18) 41% ($26–$43) Stronger Trend HRMY
Beta / 30D Volatility
Risk Regime
2.30β · 87% Vol 0.60β · 45% Vol Lower Realized Risk HRMY
Unified Institutional Score
Composite Signal
49.9 / 100 (HOLD) 57.1 / 100 (HOLD) Higher Composite HRMY
Trailing 12M Revenue (USD)
Operating Scale
$53M $989M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 74.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 29.1x EV/Rev N/M PEG · 1.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$358M ($74M Net Debt (0.38x D/E)) $323M ($498M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NTLA +0.27 pp
NTLA: -12.43% · HRMY: -12.7%
3M Horizon NTLA +0.89 pp
NTLA: -13.79% · HRMY: -14.68%
6M Horizon HRMY +32.26 pp
NTLA: -21.2% · HRMY: +11.06%
1Y Horizon NTLA +18.72 pp
NTLA: +15.34% · HRMY: -3.38%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NTLA Revenue HRMY Revenue NTLA Op. Margin HRMY Op. Margin Margin Leader
FY2018 $30M N/A -298.6% N/A NTLA
FY2019 $40M $10M -246.8% -2433.8% NTLA
FY2020 $60M $160M -235.5% 10.6% HRMY
FY2021 $30M $310M -810.4% 28.7% HRMY
FY2022 $50M $440M -879.0% 27.4% HRMY
FY2023 $40M $580M -1420.5% 33.0% HRMY
FY2024 $60M $710M -923.1% 26.7% HRMY
FY2025 $70M $870M -651.7% 24.0% HRMY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NTLA BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 78th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HRMY CONSOLIDATION
110d in phase · OBV DISTRIBUTION
Current IV 41.5%
IV Percentile 4th %ile
Put/Call OI Skew 3.37x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact HRMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NTLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
HRMY Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $2.0B market capitalization and 22.2% operating margin.
OpEx & R&D Reinvestment 51.8% of Rev ($512M)
90D Engineering Disclosures 0 Published

Investor FAQ NTLA vs HRMY Key Questions & Quantitative Answers

As of Nov 16, 2026, Harmony Biosciences Holdings, Inc. (HRMY) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NTLA carries a Unified Composite Score of 49.9/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas HRMY carries 57.1/100 (HOLD) at $33.13 (5.6x Forward P/E, 22.2% operating margin). Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile HRMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HRMY leads the Growth & Scale pillar: NTLA posts -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin), compared with HRMY at +12.3% YoY revenue growth and -6.9% YoY earnings growth on $989M TTM revenue (74.0% gross margin, 22.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NTLA cumulative revenue shifted +133.3% while HRMY shifted +8600.0%. In operating R&D and SG&A reinvestment, NTLA deploys N/A (0 90-day corporate R&D disclosures) versus 51.8% of Rev ($512M) (0 disclosures) for HRMY.

HRMY screens cheaper on headline valuation multiples. NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin), whereas HRMY trades at 5.6x Forward P/E, 11.2x Trailing P/E, N/M PEG, and 1.5x EV/Revenue (32.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NTLA (-62.6% ROE) versus HRMY (18.7% ROE) capital efficiency.

In options market volatility and institutional positioning, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk). By comparison, HRMY carries 41.5% implied volatility (4th %ile, Compressed (<25th %ile)), a 3.37x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.60β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.